{
  "id": 3664,
  "text": "Jpn J Clin Oncol 40, 90-93 (2010).1662.Tewari, K.S., et al.Improved survival with bevacizumab in advanced cervical cancer.N Engl J Med 370, 734-743 (2014).1663.Penson, R.T., et al.Bevacizumab for advanced cervical cancer: patientreported outcomes of a randomised, phase 3 trial (NRG OncologyGynecologic Oncology Group protocol 240).",
  "ChatGPT_query": "Please create a <question> that closely aligns with the provided <text>. Ensure that the <question> is formulated in Chinese and does not explicitly reference the text. You may incorporate specific scenarios or contexts in the <question>, allowing the <text> to serve as a comprehensive and precise answer.\n\n<text>: Jpn J Clin Oncol 40, 90-93 (2010).1662.Tewari, K.S., et al.Improved survival with bevacizumab in advanced cervical cancer.N Engl J Med 370, 734-743 (2014).1663.Penson, R.T., et al.Bevacizumab for advanced cervical cancer: patientreported outcomes of a randomised, phase 3 trial (NRG OncologyGynecologic Oncology Group protocol 240).\n\n<question>: ",
  "ChatGPT_response_0": "贝伐珠单抗（bevacizumab）在晚期宫颈癌中的临床效果得到了研究的关注。根据研究结果显示，使用贝伐珠单抗可以改善晚期宫颈癌患者的生存率。一项随机的第三期试验表明，患者使用贝伐珠单抗后显示出较好的生存情况。此外，病人反映出贝伐珠单抗在治疗晚期宫颈癌时也对其生活质量产生积极影响。这些研究结果表明贝伐珠单抗在晚期宫颈癌的治疗中具有潜在的临床效果。如果您想了解更多关于贝伐珠单抗在晚期宫颈癌中的临床效果，建议您可查询相关文献进一步了解。",
  "query": "什么是在晚期宫颈癌中使用贝伐珠单抗（bevacizumab）的临床效果？",
  "ChatGPT_query_a": "You are HuatuoGPT-II, equipped with in-depth knowledge in medicine. Your task is to directly answer the user's <question> in Chinese. In formulating your response, you must thoughtfully reference the <reference text>, ensuring that your reply does not disclose your reliance on <reference text>. Aim to provide a comprehensive and informative response, incorporating relevant insights from <reference text> to best assist the user. Please be cautious to avoid including any content that might raise ethical concerns.\n\n<question>: 什么是在晚期宫颈癌中使用贝伐珠单抗（bevacizumab）的临床效果？\n\n<reference text>: Jpn J Clin Oncol 40, 90-93 (2010).1662.Tewari, K.S., et al.Improved survival with bevacizumab in advanced cervical cancer.N Engl J Med 370, 734-743 (2014).1663.Penson, R.T., et al.Bevacizumab for advanced cervical cancer: patientreported outcomes of a randomised, phase 3 trial (NRG OncologyGynecologic Oncology Group protocol 240).\n\n<reply>: ",
  "response": "贝伐珠单抗（bevacizumab）在晚期宫颈癌中的临床效果得到了研究的关注。根据研究结果显示，使用贝伐珠单抗可以改善晚期宫颈癌患者的生存率。一项随机的第三期试验表明，患者使用贝伐珠单抗后显示出较好的生存情况。此外，病人反映出贝伐珠单抗在治疗晚期宫颈癌时也对其生活质量产生积极影响。这些研究结果表明贝伐珠单抗在晚期宫颈癌的治疗中具有潜在的临床效果。如果您想了解更多关于贝伐珠单抗在晚期宫颈癌中的临床效果，建议您可查询相关文献进一步了解。"
}